125969-54-2

Basic information

• Product Name: 2-(diMethylaMino)acetaldehyde, Hydrochloride
• Synonyms: 2-(diMethylaMino)acetaldehyde, Hydrochloride;(Dimethylamino)acetaldehyde hydrochloride
• CAS NO: 125969-54-2
• Molecular Formula: C₄H₉NO*ClH
• Molecular Weight: 123.5813
• EINECS: -0
• Mol File: 125969-54-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(diMethylaMino)acetaldehyde, Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(diMethylaMino)acetaldehyde, Hydrochloride(125969-54-2)
• EPA Substance Registry System: 2-(diMethylaMino)acetaldehyde, Hydrochloride(125969-54-2)

Safety Data

• Hazardous Substances Data: 125969-54-2(Hazardous Substances Data)

Usage

General Description

2-(diMethylaMino)acetaldehyde, Hydrochloride is a chemical compound belonging to the group of organic compounds known as dialkyl-amino aldehydes. 2-(diMethylaMino)acetaldehyde, Hydrochloride is characterized by a structure that contains an aldehyde group (-CHO) and two methyl groups (-CH3) attached to an amino group (-NH2). In addition, the compound contains hydrochloride, which is a monovalent inorganic anion resulting from the removal of a proton from hydrochloric acid. The presence of hydrochloride indicates that the compound is a hydrochloride salt, which generally has improved water solubility compared to the parent compound. The exact properties, such as solubility, melting point, and boiling point, can depend on other factors such as the presence of impurities. This chemical compound can be prepared in a laboratory and can be used for various applications, such as in chemical research or to perform certain chemical reactions.

Upstream product

• 38711-20-5 1,1-dimethoxymethyl-N,N-dimethylmethanamine 

Downstream Products

• 1420404-16-5 (Z)-(S)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide 
• 1420404-20-1 (E)-(S)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide 
• 1420402-21-6 (Z)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide 
• 1420402-25-0 (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide 
• 1420404-00-7 (Z)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide 
• 1420404-04-1 (E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide 
• 1443468-08-3 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid trifluoroacetate 
• 892123-49-8 C₂₀H₂₄N₄O₄ 
• 1443460-93-2 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((S)-1-acetoxy-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)ethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid 

Relevant articles and documents

A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles

Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resistance. Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors. In this paper, we demonstrate that fluoro-substituted olefins can be tuned to alter Michael addition reactivity. Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties. A lead compound 5a was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer cell lines. Additionally, compound 5a displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib. Oral administration of 5a at a dose of 30 mg/kg induced tumor regression in a murine-EGFRL858R/T790M driven H1975 xenograft model. Also, 5a exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake. These findings provide the basis of a promising strategy toward the treatment of NSCLC patients with drug resistance.